All In MedTech

Device Trial Radar · NCT07909421

A Study to Evaluate the Safety and Effectiveness of GP0112 for Cheek Augmentation and Correction of Midface Contour Deficiencies

A Randomized, Evaluator-blinded, Parallel Group, Comparator-controlled, Multicenter Study to Evaluate the Safety and Effectiveness of GP0112 for Cheek Augmentation and Correction of Midface Contour Deficiencies

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 326 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

326

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Jan 2028

Study completion Aug 2028

Sponsor

Lead sponsor
Galderma R&DNot on our public-company list
Sponsor type
Industry
First posted
Nov 2, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness of GP0112 for cheek augmentation and correction of midface contour deficiencies. Approximately 326 subjects will be randomized (1:1) to either treatment with GP0112 or Juvéderm Voluma XC(also known as Juvéderm Voluma with lidocaine).

Conditions

  • Cheek Wrinkles
  • Midface Contour Deficiencies

Interventions

  • GP0112Device

    Injectable gel

  • Juvéderm Voluma XCDevice

    Injectable gel

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Responder rate based on the Blinded Evaluators' live assessment using the Medicis Midface Volume Scale (MMVS).Time frame: At Month 6 after last treatment.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Galderma Investigational Site #6347

    Chengdu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.